Devansh MehtaGlobal Data Candidate

July 15, 2015

Cancer Is Burden Lets Be United in Our Fight Against it and Save Lives getting Ruined Unnecessarily - Unknown

Market Landscape - Breast Cancer Global

Key findings / results 1 in 2 men and 1 in 3 women will be

diagnosed with Cancer Breast cancer caused 13.1 Million

DALY(Disability Adjusted Life Years) Herceptin leading the Chart with $

6593.33 million net sales in 2014

Conclusion Breast Cancer with the leading

cancer among the women has huge market potential for Pharmaceutical and Diagnostic Industry.

Though Breast cancer is major cause of concern, Losing is not always the option.

Believe in Medical science, together we can beat it.

Market Landscape Breast Cancer “Global” What is Cancer ? Factors Responsible for Cancer Global Data of Disease Burden Breast Cancer How Breast Cancer Happens ? Global Data about Breast Cancer Breast Cancer Market Breast Cancer Diagnostic Market

Project methodology Secondary Research

Overview

Cancer Cells

Cancer: Normal Control mechanism stop working 

Old Cells Do not Die

Cells grow out of control

Cancer is the uncontrolled growth of abnormal cells in the body.

http://www.cancercenter.com/what-is-cancer/

Source: http://www.web-books.com/eLibrary/Medicine/Cancer/04MB9.html

Carcinoma in the skin or tissue

Developing Sarcomas in Bone, Cartilage, etc.

Leukemia in blood or Bone marrow

Lymphomas in Immune System

Central Nervous System Cancer

There are Five Main Categories of Cancer

http://www.cancercenter.com/what-is-cancer/

Sun and UV Exposure

Radiation Exposure

Other Carcinogens, like certain Environmental factors, (Like Asbestos factory environment)

Genetic Causes

Tobacco

Certain Diets and Physical Activity

Causes of Cancer

http://www.cancer.org/cancer/cancercauses/

Top Three, Breast, Colorectal and Lung cancer Contribute 43 % of all Cancer types

Lung Cancer Most common worldwide, 13 % of all types of Cancers

Breast Cancer (Woman Only): The 2nd most common

cancer with nearly 1.7 million new Cases in 2012.

11 % of All types of Cancer

Colorectal cancer: 9.7 % of all types of Cancer

14.1 Million Cases of Cancer Worldwide in 2012 & This number to increase to 24 million by 2035. I.e.US $ 240 Billion Cancer Market

http://www.wcrf.org/int/cancer-facts-figures/worldwide-data

This Data includes Breast Cancer deaths which according to WHO data accounts for 11 % of all types of Cancer. (i.e. 990000 cases)

It takes 12 Lakhs for Breast cancer advance stage treatment i.e. 12 Lacs * 990000 cases = Rs 1188.0 billion market i.e. US $ 18.71 Billion Dollar market by 2015.(Indian cost Inclusive)

Cost of therapy varies country by country

So, The Number is Huge and It’s a big cause of Concern for World.

The DALY associated with Breast Cancer is also too high. (DALY: Disability adjusted Life Years)

Based on projections , cancer deaths

will continue to rise with an estimated

9 million people dying from cancer in

2015, and 11.4 million dying in 2030.

Deaths Caused by this year is 4400900 by 2.35 PM 15 July, 2015, according to www.worldometers.info/cancer/

http://www.worldometers.info/cancer/

1990 to 2013, the proportion of cancer deaths as part of all deaths increased from 12 percent in 1990 to 15 percent in 2013.

Between 1990 and 2013, lost years of healthy life (disability-adjusted life years, DALYs) due to all cancers for both men and women increased by 29 percent globally.

http://www.sciencedaily.com/releases/2015/05/150528124405.htm

It Costs around € 574 million euros for complete cancer treatment

This includes, Primary care cost € 4 million euros, Outpatient care € 55 million euros, Accident and emergency € 11 million euros, inpatient care € 299 million euros, Drugs € 205 million euros.

Thus estimated market is 2028 cases * 574 = € 1164072 million euros. i.e. US $ 127320.375 billion dollar market ( Complete Cancer treatment Cost inclusive)

Denmark projects

338 cases of Cancer per 100,000 people

Denmark population is 5,627,235

i.e. 2028 cases as of 2014 population data

Denmark accounts for 2028 cases of Breast Cancer

http://blog.dana-farber.org/insight/2014/06/which-countries-have-the-highest-and-lowest-cancer-rates/

Breast Cancer is a Malignant tumor that starts in the cells of the breast.

Breast : Normal V/s Cancerous

Malignant TumorsAre CancerousMade up of cells that grow

out of control Invade nearby tissues &

Spread to other parts of the body

At times Move away from Original Cancer site & spread to other organs and bones leading to tumours to other part of the body

Lead to Secondary Cancer

Benign tumors: Aren’t CancerousCan often be removedThey Do not come backThey do not spread to other

parts of the body

Malignant cancer is the dangerous form of Cancer

https://pancreaticcanceraction.org/about-pancreatic-cancer/diagnosis/faq/difference-benign-malignant-tumour/

Most breast cancers begin in the cells that line the ducts (ductal cancers). Some begin in the cells that line the lobules (lobular cancers), while a small number start in other tissues.

http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-what-is-breast-cancer

How Breast Cancer Develops!

http://www.nationalbreastcancer.org/causes-of-breast-cancer

Previous diagnosis of breast cancer

Previous benign breast lump: Certain types of lumps not all, may lead to cancerous growth, or Breast Cancer

Higher Breast Density

Exposure to Oestrogen

Other factors like Being overweight, obesity, Being tall, Alcoholic person, Hormonal replacement therapy, Radiation.

Age: The Risk of Developing Cancer Increases with Age.

8 to 10 cases of breast cancer occur in women over 50.

Family History: Close relatives having or had ovarian cancer or breast cancer

Leading Causes of Breast Cancer

http://www.cancer.org/cancer/breastcancer/overviewguide/breast-cancer-overview-what-causes

Ductal carcinoma in situ: 80-90 % of cases

Lobular Carcinoma in situ: Limited to Milk Glands

Infiltrating ductal carcinoma: 80 % of all invasive breast cancers

Infiltrating lobular carcinoma

Inflammatory breast cancer : 1-3 % of all cases of cancer

Types of Breast Cancer

American cancer society

One in 18 women developed breast cancer between birth and age 79.

If Chemotherapy is taken into consideration It accounts to US $ 26264.7 * 13.1= US $ 344067.57 million Industry ( Taking European chemotherapy cost into consideration)

There were 1.8 million new cases and 464,000 deaths in 2013

One in 18 women developed breast cancer between birth and age 79.

 Breast cancer caused 13.1 million DALYs in 2013

http://www.sciencedaily.com/releases/2015/05/150528124405.htmhttp://oncology.jamanetwork.com/article.aspx?articleid=2294966

The New Report Suggests, Breast being 29 % of all leading causes, tops the Cancer Chart Globally.

With 810170 cases, keeping in view total cost for Cancer treatment in US to $ 10, 000 : It means the US

Market for Breast Cancer : 234949.3 cases of breast Cancer : US $ 2349493000 = US $ 2.3 billion dollar Market

234949.3 cases are estimated for Breast Cancer in US by 2015

American Cancer Society

As the Cancer comes in Chronic Disease cases, the treatment pattern for Breast Cancer is for Long term.

This is although a very bad news

Good News for Pharmaceuticals , Diagnostic Industry

With Huge Patient Base, The Market for Breast Cancer is Also Huge, Thus High potential Market for Breast Cancer in World

http://www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer

1 in 8 Is Higher Risk factor for womans in world.

Breast cancer probability is 1 in 8 per women in US

American cancer society

Estimated New Cases for Breast Cancer in US is

234190 Both sexes

2350 Males

231840 Females

The Agency for Healthcare research and Quality (AHRQ) estimates that the direct medical costs (total of all health care costs) for cancer in the US in 2011 were $88.7 billion.

Direct medical costs (total of all health care costs) for cancer in the US in 2011 were $88.7 billion.

http://www.cancer.org/cancer/cancerbasics/economic-impact-of-cancer

Average cost per month for branded drugs treatment in US is now about US $ 10, 000.

This means for Breast cancer Market is huge.

If total cases of Breast cancer in both sexes is 234190 , This means the estimated market for Breast cancer is 234190 * $10, 000 = $ 2341900000 / month

This accounts yearly basis US $ 28102800000 /yearly Market if both the sexes are taken into consideration for Breast Cancer

Reflects Annual compound growth rate of 5.4 %

In Pharmerging markets, Oncology is expected to be fourth largest or highest spend therapy class by 2017

Global Market for Oncology drugs reached $91 billion in 2013

IMS Oncology report 2014

Average cost of Chemotherapy in Europe accounts for US $ 26264.76 dollars

As in whole Europe 458337 Breast cancer cases have been noted

If Only Chemotherapy is taken into consideration

The Market size is whooping

US $ 12.03 Billion Dollars for Breast cancer/ Chemotherapy in Europe.

In US $ 2.3 Billion Market is for Breast cancer if only females are taken into consideration

This is only for US,

Since Denmark is the Leading country in terms of cancer rates, the market size would also be bigger for Breast cancer in Denmark.

However, interestingly Germany tops the Breast cancer incidence rate according to 2012 Data with 71623 Breast cancer incidence reported

231840 females with breast cancer accounts for = 231840 * 10, 000 = US $ 2318400000

http://www.imshealth.com/http://eu-cancer.iarc.fr/eucan/CancerOne.aspx?Cancer=46&Gender=2

Higher survival rate for Breast cancer directs higher Market size for the Breast Cancer drugs market

http://www.imshealth.com/

Oncology Segment Leading the Charts: Good News for Breast Cancer Market As well.

http://www.imshealth.com/

Global Oncology Market will cross US $ 117 Bn Mark by 2018

http://www.imshealth.com/

Estimated Cost for Breast Cancer treatment accounts for $ 109, 691 dollars for Perjeta and $ 59, 503 for Kadcyla

http://www.imshealth.com/

The market size for the five EU Countries is set to increase from $ 3.3 billion in 2013 to $ 5.1 billion by 2023 (3.9% CAGR)

The highest growth will be seen for HER 2 segment rising from $ 1.9 billion to $ 3.2 billion(4.7 CAGR)

Triple negative segment will grow at a CAGR of 4.3 %, from $ 180 million to $ 280 million

Sales of breast cancer drugs are set to increase by an average of 5.8 % a year in nine major markets, increasing from a value of $ 9.8 billion in 2013

to $ 18.2 billion by 2023,

According to New forecasts by IMS Health

Market Reports: Breast Cancer

http://www.pharmatimes.com/Article/14-10-02/Breast_cancer_drug_sales_will_almost_double_by_2023_says_IMS.aspx

The Figures would rise to 155863 new cases by 2015.

155863 * 12 Lakhs = Rs 1870356 lakhs / year by 2015.

i.e. Estimated market is US $ 294.5 Billion Dollar Market ( Rs. 12 lakhs estimated cost for advance stage breast cancer treatment)

Another report estimates rise upto 250, 000 new cases per year by 2015. Thus huge potential market.

Incidence of Breast Cancer in India was estimated to be 144,937 newly detected in 2012

Thus, market size for Breast cancer only if 2012 figures are taken into consideration is 144, 937 * 12 lakhs = Rs 1739244 lakhs Market / year.

I.e.= US $ 273.9 Billion Dollar Market ( Estimated Approx.)

It takes average Rs 12 lakhs for Cure of Cancer in India

http://www.breastcancerindia.net/statistics/stat_global.html

Eisai’s: Halaven (Eribulin)[ Net sales : 6280 millions, 2014]

Glaxosmithkline’s: Tyverb/Tykerb(Lapatinib) [Net sales : $ 266.64 million, sales declined by 11 %, 2014]

Roche’s: Kadcyla (Adostrastuzumab emtansine)[ Net sales: $ 561.87 million] 2014

Roche’s: Herceptin [ Increase in sales by 20 %, Net Sales : $ 6593.33 million] 2014

Novartis: Afinitor (Everolimus) [Net sales: $1600 million 2014

Astrazaneca’s: Faslodex (Fulvestrant) [Net sales: $ 720 million ] 2014 data.

Roche’s: Avastin (Bevacizumab) [$ 6726.77 million, 2014]

Novartis: Femara (Letrozole) [ $ 380 million, 2014]

Roche’s: Perjeta (Pertuzumab) [Net sales $ 962.31 million]2014

Celgene’s: Abraxane(nab-paclitaxel) [Net product sales in 2014 : $ 848 million a 31 % increase year over year.] 2014 data 2014

Top Sellers of the Breast Cancer Market: Herceptin leading the Chart with $ 6593.33 million net sales in 2014

LEE011, a CDK 4/6 inhibitor, has shown promising results in breast cancer and will be marketed soon –Novartis 2014.

http://www.pharmatimes.com/Article/14-10-02/Breast_cancer_drug_sales_will_almost_double_by_2023_says_IMS.aspx

Comparison Chart of the leading Brands for Breast Cancer Treatment

http://www.pharmatimes.com/Article/14-10-02/Breast_cancer_drug_sales_will_almost_double_by_2023_says_IMS.aspx

Urokinase plasminogen activator and plasminogen activator inhibitor (PAI-1)

Oncotype DX

Estrogen Receptor (ER) and Progestrone Receptor (PR)

Human epidermal growth factor receptor 2 (HER 2)

Cancer Antigen 15-3(CA_15-3), cancer antigen 27.29 (CA 27.29) and carcinoembryonic antigen (CEA)

Breast Cancer tumor Markers

The global market for breast cancer diagnostic and drug technologies was about $20.8 billion in 2012. This market reached about$22.3 billion in 2014 and is expected to reach $27 billion in 2019, registering a compound annual growth rate (CAGR) of 4% through 2014-2019.

http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/tumor-markers-breast-cancer

Pink chain foundation

Yoddhas Cancer Support - yoddhas.com

Breast cancer india

Vcarecancer.org

There are many NGO’s working for the support to Breast Cancer patients across Globe.

Breast Cancer is huge burden on the society

Submission for Final Round for Global Data by, Mr. Devansh Mehta,

M.Pharmacy (Pharmacology), M.B.A. in Pharmaceutical marketing and Hospital administration

Contact no: +91-8171552727

Email: devanshmehta.pharma@gmail.com